(OTC: NFRM) Reaches Agreement With Globe Laboratories

   National Pharmaceuticals Corp (PINKSHEETS: NFRM) announced yesterday that they have reached an agreement with Globe Laboratories to become National's partner to develop its drugs through the final stages.

By contacting with Globe Laboratories, National should see the speed in which its drugs are approved expedited. With 1 in 10 drugs not making final FDA approval, (http://insidebioia.com/2011/02/15/release-of-biobiomedtracker-drug-approval-rates-study/) companies like National need every advantage possible.

With many different aspects to focus on with getting a new drug to market, using a company such as Globe ensures that it is in the hands of an experienced team with a clear defined focus of their role in National's next potential marketed drug.

For more information on National Pharmaceuticals recent news release, please visit http://finance.yahoo.com/news/National-Pharmaceuticals-Corp-iw-14165390.html?x=0&.v=1

Other active stocks are Pfizer Inc (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY) and 02 Secure Wireless (PINKSHEETS: OTOW)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact: Eric Jensen www.ionewswire.com 516.942.4910